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Cordyceps sinensis is a medicinal mushroom used for centuries in Asian countries as a health supplement
and tonic. Hirsutella sinensis—the anamorphic, mycelial form of C. sinensis—possesses similar properties,
and is increasingly used as a health supplement. Recently, C. sinensis extracts were shown to inhibit the
production of the pro-inflammatory cytokine IL-1b in lipopolysaccharide-treated macrophages. However,
the molecular mechanism underlying this process has remained unclear. In addition, whether H. sinensis
mycelium (HSM) extracts also inhibit the production of IL-1b has not been investigated. In the present
study, the HSM extract suppresses IL-1b and IL-18 secretion, and ATP-induced activation of caspase-1.
Notably, we observed that HSM not only reduced expression of the inflammasome component NLRP1 and
the P2X7R but also reduced the activation of caspase-4, and ATP-induced ROS production. These findings
reveal that the HSM extract has anti-inflammatory properties attributed to its ability to inhibit both
canonical and non-canonical inflammasomes.
M
edicinal mushrooms have been used for centuries in Asia as folk medicine and natural health tonics1,2.
Mushrooms likeCordyceps sinensis,Ganoderma lucidum, andAgaricus blazeiMurrill have been used for
various human conditions, including autoimmune disease, cancer, chronic inflammation, fatigue, and
type II diabetes. Recent research has shown that these mushrooms produce antiviral, anticancer, anti-inflam-
matory, and immunomodulatory effects on cultured cells and laboratory animals. Current research efforts are
directed towards identifying the compounds responsible for mediating these biological effects, with polysacchar-
ides and nucleosides appearing as major candidates1,2.
C. sinensis (also termed Ophiocordyceps sinensis) is an ascomycete fungus that possesses a peculiar mode of
growth characterized by two main stages; the first stage is characterized by the fungus infecting underground
caterpillar larvae in the winter, whereas the second stage is associated with the production of a fruiting body that
protrudes from the dead caterpillar’s head and grows above the ground during the summer3–7. For this reason, C.
sinensis is known as the ‘‘caterpillar fungus’’ or ‘‘dong-chong-xia-cao’’ (literally ‘‘winter worm, summer grass’’ in
Chinese)6–8. The growth of this natural fungus is also unusual due to the fact that it is limited to the Tibetan plateau
and southwestern China, and it usually grows at or even below the relatively low temperature of 18uC4,5,9. Recent
studies indicate that C. sinensis has a wide range of biological activities, including anti-tumor10,11, immunomo-
dulatory12,13, anti-inflammatory14,15, anti-oxidant16,17, anti-infection18, and anti-aging properties19.
Due to the rarity of natural C. sinensis, other means of producing this fungus have been investigated. The
identity of the anamorph of C. sinensis has been a topic of considerable controversy in the past20. Hirsutella
sinensis, which today is widely accepted as the true anamorphic, mycelial stage of naturalC. sinensis20, is amenable
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to culture in vitro, and is increasingly used as a health supplement.
Studies of the pharmacological properties of HSM have shown that it
possesses biological activities similar to that of the wild mushroom.
For instance, these activities include reduction of drug-induced leu-
copenia following kidney transplantation, amelioration of radiation-
induced toxicity, and stimulation of immune cells in vivo21,22. Earlier,
we demonstrated that HSM prolongs survival and decreases symp-
tom severity in a murine model of the systemic autoimmune disease,
lupus erythematosus23. However, the mechanism underlying the
immunosuppressive effects of HSM is still unclear.
Methanol extracts of natural C. sinensis have been shown to sup-
press bronchoalveolar lavage fluid (BALF) cell proliferation and to
reduce IL-1b, IL-6, IL-8, IL-10 and tumor necrosis factor (TNF)-a
production in LPS-activated BALF cell cultures24. Li et al. reported
that C. sinensis water extracts reduce the production of the pro-
inflammatory cytokines IL-1b, IL-6, TNF-a, and IL-12p70 in LPS-
activated dendritic cells25. Nonetheless, whether HSM possesses
similar activities has not been investigated.
Macrophages are differentiated immune cells that originate as
blood monocytes and are found in tissues throughout the body.
These immune cells play an essential role during initiation and pro-
pagation of inflammatory responses by producing pro-inflammatory
cytokines such as IL-1b, IL-18, and TNF-a, as well as other inflam-
matorymediators like nitric oxide and prostaglandins26–28. IL-1b and
IL-18, which are members of the IL-1 cytokine superfamily, promote
a variety of innate immune processes associated with infection,
inflammation, and autoimmunity29,30. IL-1b participates in the gen-
eration of systemic and local immune responses against various
strains of pathogens, and has been implicated in the pathogenesis
of inflammatory diseases, such as gout, asthma, inflammatory bowel
diseases, rheumatoid arthritis, and atherosclerosis31–33. IL-18 also
plays a critical role in the execution of anti-microbial and anti-viral
immunity, and this cytokine has been associated with severe inflam-
matory disorders, such as rheumatoid arthritis, Crohn’s disease,
psoriasis, lupus, sarcoidosis, and multiple sclerosis34,35.
The pro-inflammatory cytokines, IL-1b and IL-18, are synthesized
as inactive precursors (i.e., pro-IL-1b and pro-IL-18) and accumulate
within the cytosolic compartment of monocytes and macrophages
exposed to or ‘‘primed’’ with pathogen-associatedmolecular patterns
(PAMPs) like the bacterial endotoxin LPS36. However, LPS by itself is
usually insufficient to trigger IL-1b and IL-18 secretion frommacro-
phages unless danger-associated molecular patterns (DAMPs) pro-
vide the second signal responsible for the activation of the
inflammasome complex, activation of the protease caspase-1, pro-
cessing of pro-IL-1b and pro-IL-18, and release of the mature cyto-
kines from the cells37–39.
Extracellular adenosine 59-triphosphate (ATP) acts as a danger
signal released from injured cells during tissue damage and inflam-
mation; it initiates inflammation and further amplifies and sustains
cell-mediated immunity through P2 receptor-mediated purinergic
signaling40,41. Binding of ATP to the P2X7 receptor (P2X7R) in
primed monocytes and macrophages leads to inflammasome activa-
tion and secretion of pro-inflammatory cytokines IL-1b and IL-1842.
Inflammasomes represent a group of cytoplasmic multiprotein
complexes whose assembly leads to activation of the cysteine prote-
ase caspase-1, which promotes the proteolytic processing of the
immature forms of IL-1b and IL-1843. The inflammasome complex
is typically formed by three components consisting of a nucleotide
binding and oligomerization domain (NOD)-like receptor (NLR),
the ASC adaptor protein (for apoptosis-associated speck-like protein
containing a caspase recruitment domain), and pro-caspase-1. Upon
activation, oligomerized NLRs interact with ASC, which in turn
recruits and activates caspase-1 and leads to cleavage and activation
of pro-IL-1b and pro-IL-1839. TheNLRP1 (nacht, leucine-rich repeat
and pyrin domain containing domain-1; also known as NALP1,
NAC, CARD7, DEFCAP, or CLR17.1) and NLRP3 (also known as
NALP3, cryopyrin, CIAS1, or PYPAF1) inflammasomes are two of
the best-characterized canonical inflammasomes described so far. A
large number of stimuli have been shown to trigger activation of the
NLRP3 inflammasome, including ATP, monosodium urate crystals,
cholesterol crystals, UVB irradiation, pathogen-derived nucleic
acids, silica, asbestos, and amyloid-b44–51. LPS and muramyl dipept-
ide (MDP) along with ATP have been reported to induce NLRP1
inflammasome assembly, caspase-1 activation and cleavage of pro-
IL-1b into its active form52,53.
More recently, non-canonical inflammasomes containing murine
caspase-11 have also been reported54,55. Caspase-11 does not exist in
humans, but is functionally equivalent to caspase-4 and caspase-5,
which also modulate inflammasome activity56,57.
C. sinensis extracts were previously shown to inhibit the produc-
tion of IL-1b in LPS-stimulated macrophages. However, the molecu-
lar mechanism responsible for this inhibition was not characterized,
and the possibility that IL-18 secretion may also be affected was not
investigated. The main objective of the present study was to deter-
mine whether ethanol extracts of HSM have an inhibitory effect on
the production of IL-1b and IL-18 in LPS-primed human macro-
phages. In addition, we examined whether the HSM ethanol extract
can modulate inflammasome activation in macrophages. We dem-
onstrate that HSM ethanol extract suppresses IL-1b and IL-18 secre-
tion. The reduction of IL-1b and IL-18 production is associated with
down-regulation of NLRP1, a component of one of the canonical
inflammasomes. HSM also inhibits the transcription and activation
of both caspase-1 and caspase-4, the latter being associated with non-
canonical inflammasomes. Furthermore, ATP-induced ROS genera-
tion and P2X7R activation are suppressed by HSM.
Results
Absence of toxicity of the HSM ethanol extract on human macro-
phages. Whether ethanol extracts of HSM have cytotoxic effects on
human cells has not been studied. Therefore, we first determined the
effects of the HSM extract on the viability of THP-1 macrophages
using the MTT assay. Treatment of the cells with either 1 or 2% (v/v)
of the HSM ethanol extract for 24 h did not affect cell viability,
compared with HSM-untreated control cells (Figure 1). However,
cell viability was significantly decreased when the cells were
incubated with 5% of HSM ethanol extract for the same period of
Figure 1 | Absence of toxicity due to HSM treatment of human
macrophages. Cells were treated with 1 to 5% of HSM ethanol extract for
24 h, and cell viability was measured by the MTT assay, as described in
Materials and Methods. Data are presented as means 6 SE of three
experiments preformed in duplicate. *P , 0.01 versus HSM-untreated
control cells.
www.nature.com/scientificreports
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time (Figure 1). Based on these results, we used the HSM extract at a
concentration of 1 or 2% in subsequent experiments.
HSM extract reduces ATP-induced IL-1b and IL-18 secretion in
LPS-primed macrophages.We examined whether the HSM extract
affects IL-1b and IL-18 gene expression in THP-1 macrophages. We
first pre-treated the macrophages with the HSM ethanol extract (1 or
2%) for 20 h, then with LPS (0.5 mg/ml) for 3 h to induce cytokine
expression, and finally with ATP (5 mM) for 1 h to activate the cells
and induce secretion of IL-1b and IL-18. RT-PCR and quantitative
real-time PCR analyses showed that HSM pre-treatment increased
the mRNA expression levels of IL-1b and IL-18 in a dose-dependent
manner (Figure 2a, 2b, 3c, and 3d).
We then determined the concentrations of secreted IL-1b and IL-
18 proteins in the cell culture supernatants of the same ATP-acti-
vated macrophages. ELISA and Western blot analyses revealed that
pre-treatment of the cells with HSM significantly reduced the secre-
tion of IL-1b and IL-18 in a dose-dependent manner (Figure 2c, 2d,
3c, and 3d). These findings indicate that the HSM extract stimulates
expression of the cytokines, but decreases their secretion in response
to ATP treatment.
HSM extract suppresses ATP-induced caspase-1 activation in
macrophages. The cytokines IL-1b and IL-18 are generated as
cytosolic precursors that require cleavage by the protease caspase-1
in order to generate biologically active cytokines. Caspase-1 itself is
activated by several innate immune complexes termed inflamma-
somes37. To determine whether caspase-1 gene expression and
activation are affected by the HSM ethanol extract, we pre-
incubated THP-1 macrophages with HSM for 20 h prior to LPS
and ATP treatments as mentioned above. As shown in Figure 4a
and 4b, the HSM extract decreased caspase-1 mRNA expression in
the activated macrophages treated with LPS and ATP. The HSM
extract also significantly inhibited ATP-induced caspase-1 activa-
tion (secretion) in a dose-dependent manner (Figure 4c and 4d).
These results suggest that the ability of HSM to decrease secretion
Figure 2 | Effects of HSM on IL-1b gene expression and secretion in human macrophages. Cells were pre-treated with either 1 or 2% of HSM
extract for 20 h, followed by treatment with LPS (0.5 mg/ml) for 3 h and with ATP (5 mM) for 1 h. (a) The mRNA expression levels of IL-1b were
determined by RT-PCR analysis. (b) IL-1bmRNAs were quantified using real-time PCR. b-actin gene expression was used for normalization. The results
are expressed as fold changes, considering one as the value of untreated cells. (c) The amount of IL-1b in cell culture supernatants was detected by ELISA.
(d) The presence of IL-1b in cell lysates and cell culture supernatants were analyzed by Western blot analysis. Data are presented as means 6 SE of three
experiments performed in duplicate. #P, 0.01 versus untreated cells. *P, 0.01 versus HSM-untreated (ethanol-treated) control cells. {P, 0.05 versus
HSM (1%) treated cells.
www.nature.com/scientificreports
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of IL-1b and IL-18 is due at least in part to reduced caspase-1 gene
expression and protein activation in the treated macrophages.
HSM extract inhibits NLRP1 inflammasome expression and caspase-
4 activation in ATP-treated macrophages. Several inflammasome
complexes, including the NLRP1 and NLRP3 inflammasomes,
have been shown to activate caspase-1. Canonical inflammasomes
are formed by three components that include an NLR family protein
(e.g., NLRP1 or NLRP3), the adaptor protein ASC, and pro-caspase-
158. To examine whether the NLRP1 and NLRP3 inflammasomes
may be involved in the anti-inflammatory activity of HSM, we
measured the mRNA and protein expression levels of NLRP1,
NLRP3, and ASC using RT-PCR, quantitative real-time PCR, and
Western blot analyses. As shown in Figure 5a–c, pre-treatment of
the cells with HSM decreased NLRP1 mRNA and protein levels
compared to cells treated only with LPS and ATP. Conversely, the
expression of NLRP3, which was clearly induced by LPS and ATP,
was further increased in cells pretreated with HSM (Figure 5a–c). In
addition, the level of ASC expression, which decreased following LPS
and ATP treatments, appeared unchanged by HSM pre-treatment.
These results suggest that the HSM extract may reduce IL-1b and IL-
18 secretion by down-regulating NLRP1.
Recent studies have shown that pro-IL-1b and pro-IL-18 are
also substrates of non-canonical inflammasomes containing the
protease caspase-4, and that this proteolytic enzyme is able to
generate the biologically active form of the cytokines56,59. To deter-
mine whether the HSM extract may affect caspase-4 gene express-
ion in macrophages treated with LPS and ATP, we performed RT-
PCR and quantitative real-time PCR assays using caspase-4 spe-
cific primers. As shown in Figure 5a and 5b, pre-treatment with
HSM resulted in a significant decrease of caspase-4 gene express-
ion in LPS-primed macrophages stimulated with ATP. Western
blot analysis of HSM-treated cells also showed a significant reduc-
tion of active caspase-4 in cell lysates (Figure 5d). Taken together,
Figure 3 | Effects of HSM on IL-18 gene expression and secretion in human macrophages. Cells were pre-treated with various concentrations
(1 or 2%) ofHSM extract for 20 h, followed by treatment with LPS (0.5 mg/ml) for 3 h andATP (5 mM) for 1 h. (a) ThemRNA expression levels of IL-18
were determined by RT-PCR analysis. (b) IL-18 mRNAs were quantified using real-time PCR. b-actin gene expression was used for normalization. The
results are expressed as fold changes, considering one as the value of untreated cells. (c) The amount of IL-18 in cell culture supernatants was detected by
ELISA. (d) The presence of IL-18 in cell lysates and cell culture supernatants were analyzed byWestern blot analysis. Data are presented as means 6 SE of
three experiments performed in duplicate. #P , 0.01 versus untreated cells. *P , 0.01 versus HSM-untreated control (ethanol) cells. {P , 0.05 versus
HSM (1%) treated cells.
www.nature.com/scientificreports
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these results suggest that the HSM-mediated reduction of IL-1b
and IL-18 secretion by macrophages is due to both down-regu-
lation of the NLRP1 inflammasome, and decreased activity of
caspase-4.
HSM extract down-regulates P2X7 receptor expression and ROS
production in LPS-primed and ATP-stimulated macrophages.
Previous studies have shown that activation of the purinergic
receptor P2X7R by extracellular ATP is required for caspase-1
activation, a process that leads to processing and release of both
caspase-1 and mature IL-1b into the culture medium of activated
macrophages60–62.
To determine whether the HSM extract may influence expression
of P2X receptors (i.e., ATP-gated channels), we pre-treated THP-1
macrophages with HSM extract (1 or 2%), and then with LPS and
ATP, prior to measuring the mRNA and protein expression levels of
P2X7R and P2X4R (receptor for lower concentrations of ATP than
P2X7R) using RT-PCR, quantitative real-time PCR, and Western
blot analyses. As shown in Figure 6a–c, the up-regulation of
P2X7R expression induced by ATP (and LPS) was suppressed in a
dose-dependent manner by pre-treatment by the HSM extract. In
comparison, the up-regulation of P2X4R expression induced by ATP
was not affected by HSM treatment.
Previous studies have reported that activation of the P2X7R by
ATP induces the production of ROS which are also required for
activation of caspase-1 and secretion of IL-1b and IL-1863,64. To test
whether the ROS production induced by ATP is also affected by
HSM, we used a commercially-available detection kit to measure
ROS production in macrophages that were pre-treated with HSM,
prior to LPS priming and ATP activation. ATP treatment in LPS-
primed macrophages caused a significant increase of ROS produc-
tion compared with untreated cells (Figure 6d; pyocyanin was used
as a positive control for ROS formation). The increase in ROS pro-
duction could be suppressed by pre-treating macrophages with HSM
extract (Figure 6d). Taken together, these results indicate that the
HSM ethanol extract reduces IL-1b and IL-18 secretion in activated
Figure 4 | Effects ofHSMonATP-mediated caspase-1 gene expression and activation in humanmacrophages. Cells were pretreated withHSM extracts
(1 or 2%) for 20 h, followed by treatment with LPS (0.5 mg/ml) for 3 h and subsequently ATP (5 mM) for 1 h. (a) The mRNA expression levels of
caspase-1 were determined by RT-PCR analysis. (b) Caspase-1 mRNAs were quantified using real-time PCR. b-actin gene expression was used for
normalization. The results are expressed as fold changes, considering one as the value of untreated cells. (c) The secretion of caspase-1 subunit p20 into the
supernatants of THP-1 macrophages was assessed by ELISA. (d) Cell lysates and culture supernatants were Western-blotted to detect pro-caspase-1 p45
and caspase-1 subunit p20. Data are presented as means 6 SE of three experiments preformed in duplicate. #P, 0.01 versus untreated cells. *P, 0.01
versus HSM-untreated control (ethanol) cells. {P , 0.05 versus HSM (1%) treated cells.
www.nature.com/scientificreports
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macrophages in part by down-regulating the ATP purinergic recep-
tor P2X7R and reducing ATP-induced ROS production.
Discussion
C. sinensis is a well-known traditional Chinese medicinal mushroom
used for the treatment of a variety of human diseases such as liver
disease, respiratory disease, renal dysfunction, heart disease, hyper-
glycemia, and hyperlipidaemia6,7. Recent studies have demonstrated
that C. sinensis possesses immunomodulatory properties that,
depending on the context, both activate and inhibit the immune
system12,65,66. In the present study, we evaluated the effects of an
HSM ethanol extract on the secretion of IL-1b and IL-18 induced
by ATP in LPS-primed macrophages. We observed that pre-treat-
ment with the HSM ethanol extract reduced the production of pro-
inflammatory cytokines IL-1b and IL-18 in these cells. This finding is
consistent with previous reports showing that C. sinensis extracts
down-regulate the production of IL-1b in other LPS-activated
immune cells24,25. However, our results also show that the HSM
extract increases the transcription levels of the IL-1b and IL-18 pre-
cursors in LPS-primed and ATP-stimulated macrophages. Previous
studies have reported that Cordyceps militaris, another Cordyceps
species which is different from both natural C. sinensis and cultured
HSM, induces IL-1b and IL-18 mRNA expression in murine
RAW264.7 macrophages67,68. Our results indicate that the HSM
extract suppresses the production of IL-1b and IL-18 through a
mechanism other than inhibition of mRNA expression.
Since the inflammasomes are involved in IL-1b and IL-18 secre-
tion, we investigated whether the reduced IL-1b and IL-18 secretion
in HSM-treated cells was mediated by these molecular complexes.
Assembly of the inflammasomes results in activation of the protease,
caspase-1. Activated caspase-1 is responsible for processing of pro-
IL-1b and pro-IL-18 and secretion of the mature cytokines37. Our
results show that LPS-primed macrophages pre-incubated with the
HSM extract causes decreased activation of caspase-1 in ATP-treated
Figure 5 | Effects of HSM on inflammasome components and caspase-4 activation in human macrophages. Cells were pretreated with various
concentrations (1 or 2%) of HSM extract for 20 h, followed by treatment with LPS (0.5 mg/ml) for 3 h and ATP (5 mM) for 1 h. (a) The mRNA
expression levels of ASC, NLRP1, NLRP3 and caspase-4 were determined by RT-PCR, using b-actin as the internal control. (b) ASC, NLRP1, NLRP3 and
caspase-4 mRNAs were quantified using real-time PCR. b-actin gene expression was used for normalization. The results are expressed as fold changes,
considering one as the value of untreated cells. (c) Cell lysates were analyzed by Western blot analysis using specific anti-ASC, anti-NLRP1 and anti-
NLRP3 antibodies. (d) Cell lysates were analyzed for protein levels of caspase-4 byWestern blot analysis. b-actin was used as an internal control. Data are
presented as means 6 SE of three experiments preformed in duplicate. #P , 0.01 versus untreated cells. P , 0.05 versus HSM-untreated control
(ethanol) cells. *P , 0.01 versus HSM-untreated control (ethanol) cells.
www.nature.com/scientificreports
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macrophages. Treatment with HSM also decreases caspase-1 mRNA
expression.
Greten et al. demonstrated previously that activation of the nuc-
lear transcription factor NF-kB induces pro-IL-1bmRNA synthesis
and inhibits caspase-1 activation in macrophages69. In addition, NF-
kB is activated in response to various inflammatory stimuli, includ-
ing bacterial LPS, cytokines, and viral infection70. Based on these
results, we suggest that the HSM extract may activate NF-kB and
lead to induction of pro-inflammatory cytokines IL-1b and IL-18
precursors and to inhibition of capase-1 activation in macrophages
treated with LPS and ATP.
Our mechanistic studies show that HSM-dependent reduction of
IL-1b and IL-18 production is due to a specific down-regulation of
the NLRP1 inflammasome and subsequent inhibition of caspase-1
activity. A recent study by Hsu et al. showed that MDP stimulation
induces the association of NOD2withNLRP1 to form a complex that
activates caspase-1 and triggers processing and secretion of IL-1b in
macrophages71. NLRP1 also plays a crucial role in Bacillus anthracis-
induced IL-1b secretion71. Additionally, THP-1monocytes that were
differentiated into macrophages with phorbol 12-myristate 13-acet-
ate (PMA) and further treated with LPS or MDP plus ATP induced
NLRP1 inflammasome assembly, caspase-1 activation, and IL-1b
secretion52,53.
To our knowledge, our study is the first report demonstrating the
effects of HSM extract on an inflammasome in THP-1 macrophages
activated with LPS and ATP. Furthermore, we make the unexpected
observation that a mushroom used in traditional medicine can also
activate a non-canonical inflammasome. However, the HSM ethanol
extract studied here also increased NLRP3 mRNA and protein levels
in the activated macrophages. Recent evidence indicates that NLRP3
expression is tightly controlled by the activation of NF-kB, and that
NF-kB inhibition leads to a dose-dependent reduction of NLRP3
protein induced by LPS72. This finding further supports the possibil-
ity that the HSM extract may induce NF-kB activation, which also
Figure 6 | Effects of HSM on the expression of P2X4R and P2X7R and ROS production in human macrophages. Cells were pretreated with various
concentrations (1 or 2%) of HSM extract for 20 h, followed by treatment with LPS (0.5 mg/ml) for 3 h and ATP (5 mM) for 1 h. (a) The mRNA
expression levels of P2X4R and P2X7R were determined by RT-PCR, using b-actin as the internal control. (b) P2X4R and P2X7RmRNAs were quantified
using real-time PCR. b-actin gene expression was used for normalization. The results are expressed as fold changes, considering one as the value of
untreated cells. (c) Cell lysates were analyzed by Western blot analysis used specific anti-P2X4R and anti-P2X7R antibodies. (d) ROS production was
measured with the total ROS detection kit, using a fluorescencemicroplate reader. Pyocyanin (200 mM), a ROS inducer, was used as a positive control for
ROS formation. Data are presented as means 6 SE of three experiments preformed in duplicate. #P, 0.01 versus untreated cells. P, 0.05 versus HSM-
untreated control (ethanol) cells. *P , 0.01 versus HSM-untreated control (ethanol) cells. {P , 0.05 versus HSM (1%) treated cells.
www.nature.com/scientificreports
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increases NLRP3 expression and induces accumulation of IL-1b and
IL-18 precursors in LPS-primed and ATP-stimulated macrophages.
ATP-induced P2X7R activation promotes the production of ROS,
which in turn stimulates activation of the NLRP3 inflammasome63.
In this study, we demonstrated that pre-treatment of LPS-primed
macrophages with HSM extract significantly inhibits ATP-induced
P2X7R expression. Moreover, our results show that ATP-induced
ROS production is suppressed by the HSM extract. In agreement
with these findings, previous studies have shown that theH. sinensis
preparation CorImmune displays antioxidant activity and protects
tissues and cells against free radical-induced damage73,74. Anti-oxid-
ant activity was also reported for natural C. sinensis, and this activity
might be derived partly from the polysaccharide fraction of C. sinen-
sis water extracts75. Recently, caspase-4 expression was shown to be
required for caspase-1 activation and maturation of pro-IL-1b and
pro-IL-18 in keratinocytes and activated THP-1 macrophages, sug-
gesting that caspase-4 may act upstream of a non-canonical inflam-
masome56. Interestingly, production of ROS plays an important role
in ER stress induction, which further leads to proteolytic cleavage of
caspase-476,77. To address whether caspase-4 expression and activa-
tion is also regulated by HSM, we examined the expression of cas-
pase-4 in activated macrophages. Pre-treatment of the cells with
HSM resulted in a significant reduction of caspase-4 expression
and activation compared with control, untreated cells. These results
indicate that HSM compounds may act upstream of the inflamma-
some and result in down-regulation of caspase-1 activation and
reduced IL-1b and IL-18 secretion.
We are currently investigating the compounds responsible for
producing the anti-inflammatory effects of HSM. The nucleoside
derivative 39-deoxyadenosine—also called ‘‘cordycepin’’—has been
described in the past as an active ingredient ofC. sinensis extracts78–80.
Studies have shown that synthetic cordycepin produces anti-inflam-
matory effects on cultured cells81–83. However, chemical analyses
performed by other groups showed that, while cordycepin is found
in C. militaris, this compound is usually absent in both natural C.
sinensis fruiting bodies and cultured HSM84,85. In fact, our own high-
performance liquid chromatography analysis confirmed that cordy-
cepin is not detected in the HSM ethanol extract studied here (Y.-F.
Ko, J. D. Young, unpublished observations). Our preliminary chem-
ical analysis of the HSM ethanol extract indicates that the com-
pounds responsible for the anti-inflammatory effects of HSM have
molecular weights ranging from 400 to 1,500 Da, but that neither
polysaccharides nor adenosine can be detected in the extract (Y.-F.
Ko, J. D. Young, unpublished observations). Structural studies are in
progress in our laboratories to identify the chemical nature of this
anti-inflammatory activity.
In conclusion, our results demonstrate that the HSM extract is a
potent inhibitor of ATP-induced caspase-1 activation and secretion
of IL-1b and IL-18 in LPS-primed human macrophages. Figure 7
summarizes the intracellular pathways affected by the HSM extract.
The reduction of IL-1b and IL-18 secretion by the HSM ethanol
extract in activated macrophages is associated with inhibition of
P2X7R expression, ROS production, NLRP1 expression, and cas-
pase-1 and caspase-4 activation.
The cytokines IL-1b and IL-18 can induce inflammation, fever,
and tissue damage in humans. Blocking secretion of these cytokines
with HSM could represent a viable strategy to relieve symptoms
associated with inflammatory disorders such as asthma, rheumatoid
arthritis, inflammatory bowel disease, and other autoimmune
diseases.
Figure 7 | Schematic model for the reduction of IL-1b and IL-18 secretion in LPS-primed and ATP-stimulated macrophages treated with HSM. The
HSM extract down-regulated P2X7R expression, ROS production, NLRP1 expression, and caspase-1 and caspase-4 activation, which together inhibited
the secretion of IL-1b and IL-18. TLR4: Toll-like receptor 4.
www.nature.com/scientificreports
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Methods
Chemicals and reagents. ATP, LPS and PMA were purchased from Sigma-Aldrich
(St. Louis, MO). Cell culture medium (RPMI 1640), FBS, penicillin and streptomycin
were purchased from Life Technologies (Grand Island, NY). For Western blot
analysis, the antibodies against IL-1b and caspase-4 were obtained from Cell
Signaling Technology (Beverly,MA); the ones against ASC, P2X7R, pro-IL-1b and IL-
18 were from Santa Cruz Biotechnology (Santa Cruz, CA); and those against NLRP3
and P2X4R were from Sigma-Aldrich. The antibody directed against caspase-1 was
purchased fromMillipore (Billerica, MA); the one against NLRP1 was from Enzo Life
Sciences (Farmingdale, NY); and the one against b-actin was from Novus Biologicals
(Littleton, CO). The secondary antibodies used were horseradish peroxidase-
conjugated anti-rabbit and anti-mouse IgGs (Santa Cruz Biotechnology).
Fungal strain and preparation of the ethanol extract. The H. sinensis strain
originally selected and characterized at Chang Gung Biotechnology (Taipei, Taiwan)
was validated by comparison of its internal transcribed spacer DNA with that of
natural C. sinensis23. The ethanol extract was prepared by adding 400 g of H. sinensis
mycelium powder to 10 liters of 95% ethanol (v/v) into a Buchi R220 vacuum
concentrator (Zurich, Switzerland), followed by stirring at a speed of 120 rpm for
60 min at 80uC. The HSM solution was cooled to room temperature and centrifuged
at 4,500 rpm for 30 min at 4uC using a Sorvall RC 3C Plus centrifuge (Thermo Fisher
Scientific, Waltham, MA). The supernatant was collected and concentrated to a final
volume of 2 liters by using the Buchi R220 vacuum concentrator at 65uC. The HSM
ethanol extract was finally sterilized by filtration through a 0.45 mm filter (Millipore),
and stored at 4uC in dark glass bottles until use.
Cell culture and treatments. Human acute monocytic leukemia THP-1 cells
(American Type Culture Collection, TIB-202) were cultured in RPMI 1640 medium
supplemented with 10% (v/v) heat-inactivated FBS, 100 units/ml of penicillin, and
100 mg/ml of streptomycin. THP-1 cells were incubated at 37uC in a cell culture
incubator containing 5% CO2 and saturated humidity. The experiments were
performed with cells plated in 6-well plates at 2 3 106 cells per well. The cells were
differentiated to adherent macrophages by overnight culture in complete medium
supplemented with 500 ng/ml of PMA, and then with fresh complete medium for an
additional 2 days. THP-1 macrophages were pre-treated for 20 h with 1 or 2% of
HSM extract or with 2% ethanol as a control, followed by treatments with LPS
(0.5 mg/ml) for 3 h and ATP (5 mM) for 1 h. Cell culture supernatants were
harvested at 14,000 3 g for 5 min at 4uC, and the supernatants were collected and
stored at –80uC for cytokine assay. In addition, cell lysates were resuspended in lysis
buffer for RNA extraction and Western blot analysis.
MTT assay for cell viability.Cell viability was determined using a commercial MTT-
based cytotoxicology test kit (Sigma-Aldrich), which detects viable cells
colorimetrically based on the detection of the purple formazan compound produced
by viable cells. THP-1 cells were initially seeded in 96-well plates (1 3 105 cells/well)
for 24 h. For macrophage differentiation, cells were treated and incubated with PMA
as described above. Cell culture media were replaced by complete media containing
different concentrations of HSMextract ranging from1 to 5%, followed by incubation
for 24 h. After incubation, 10 ml of MTT (5 mg/ml) were added to each well, and the
plates were incubated at 37uC for 4 h. Each well was eluted and the precipitates were
dissolved with 100 ml of MTT solubilization solution. Cell viability was obtained by
calculating absorption values at 570 nm using a VersaMax microplate ELISA reader
(Sunyvale, CA). All treated samples and controls were tested in triplicate.
Enzyme linked immuno sorbent assay (ELISA).THP-1macrophages (23 106 cells/
well) in 6-well culture plates were pre-incubated with the HSM extract (1 or 2%) in
1 ml of complete medium for 20 h, followed by treatment with LPS (0.5 mg/ml) for
3 h and treatment with ATP (5 mM) for 1 h. Cell culture supernatants were collected
and centrifuged at 10,000 3 g, 4uC for 5 min to remove cell debris. Levels of secreted
IL-1b, IL-18 and activated caspase-1 in cell culture supernatants weremeasured using
commercially available ELISA kits (R&D Systems, Minneapolis, MN) according to
the manufacturer’s instructions.
Measurement of ROS production. Total ROS/Superoxide detection kit (Enzo Life
sciences) was used to assess ROS production in THP-1 macrophages. Briefly, cells
were first seeded (1 3 105 cells/well) in 96-well culture plates for 24 h. For
macrophage differentiation, cells were treated and incubated with PMA in as
described above. Cell media were replaced by complete media containing different
concentrations of HSM extract (1 or 2%) and then incubated for 20 h, followed by
treatment with LPS (0.5 mg/ml) for 3 h and treatment with ATP (5 mM) for 1 h.
In addition, cells were treated with the ROS inducer pyocyanin (200 mM), as a
positive control, for 30 min at 37uC. After treatment, cells were washed with
200 ml of 13 wash buffer and loaded with 100 ml of ROS/Superoxide detection
reagents, and then incubated at 37uC for 1 h. The plates were read using a
VersaMax microplate ELISA reader (Sunyvale, CA) at 520 nm after excitation at
488 nm. The increase in relative fluorescence intensity was used to determine
intracellular ROS production.
Protein extraction and western blot analysis. Cell extracts and cell culture
supernatants were analyzed by Western blot analysis. Twenty hours after HSM
treatment, cells were treated with LPS (0.5 mg/ml) for 3 h and subsequently with ATP
(5 mM) for 1 h. TheHSM-treated cells werewashed twice with PBS and suspended in
RIPA lysis buffer (50 mM Tris-HCl, pH 7.4, 150 mMNaCl, 0.25% deoxycholic acid,
1%Nonidet P-40, 1 mMEDTA) (Millipore) and complete protease inhibitor cocktail
(Roche, Mannheim, Germany). Cell suspensions were incubated on ice for 30 min
and centrifuged at 15,0003 g for 30 min at 4uC. The supernatants of cell suspensions
were harvested as described above and stored at –80uC. Total protein concentration
was determined using the Bio-Rad Bradford assay (Herculus, CA). Proteins were
separated by electrophoresis in 8-to-12% SDS-polyacrylamide gels and transferred
onto Millipore PVDF membranes. Specific proteins were detected using the
appropriate primary and secondary antibodies before visualization using enhanced
chemiluminescence detection kit (Millipore).
RNA isolation and reverse transcriptase-polymerase chain reaction (RT-PCR)
analysis. Total RNA was extracted from THP-1 cells using total RNA mini-kit
according to the manufacturer’s instructions (Geneaid, Taipei, Taiwan). Two mg of
RNA were reversely transcribed in a reaction volume of 20 ml which contained an
oligo (dT) primer, dNTP, and the SuperScriptTM III reverse transcriptase (Invitrogen,
Carlsbad, CA). The cDNA for ASC, caspase-1, caspase-4, IL-1b, IL-18, NLRP1,
NLRP3, R2X4R, P2X7R and b-actin were amplified by PCR using the following
specific primers: ASC forward primer 59-ATCCAGGCCCCTCCTCAGT-39, and
reverse primer 59-GTTTGTGACCCTCCGCGATAAG-39; caspase-1 forward primer
59-GAATGTCAAGCTTTGCTCCCTAGA-39, and reverse primer 59-AAGACG-
TGTGCGGCTTGACT-39; caspase-4 forward primer 59-GGTCATCATTGT-
CCAGGC-39, and reverse primer 59-CCATTGTGCTGTCTCTCC-39; IL-1b forward
primer 59-AAAAGCTTGGTGATGTCTGG-39, and reverse primer 59-TTTCAA-
CACGCAGGACAGG-39; IL-18 forward primer 59-GCTGAACCAGTAGAA-
GACAATTG-39, and reverse primer 59-ATCTGATTCCAGGTTTTCATCATCT-39;
NLRP1 forward primer 59-ACCTGATCCCAAGTGACTGC-39, and reverse primer
59-TCTTCTCCAGGGCTTCGATA-39; NLRP3 forward primer 59-CTTCTCTG-
ATGAGGCCCAAG-39, and reverse primer 59-GCAGCAAACTGGAAAGGAAG-
39; P2X4R forward primer 59-GGATGTGGCGGATTATGTGATAC-39, and reverse
primer 59-AGTGGTCGCATCTGGAATCTC-39; P2X7R forward primer 59-TGTG-
CCTACAGGTGCTACGCC-39, and reverse primer 59-GCCCTTCACTCTTCG-
GAAACTC-39; and b-actin forward primer 59-GAGACCTTCAACACCCCAGCC-
39, and reverse primer 59-GGATCTTCATGAGGTAGTCAG-39. Amplified PCR
products were electrophoresed in a 2% agarose gel and visualized by ethidium
bromide (Sigma-Aldrich) staining using a standard image system.
Quantitative real-time PCR analysis. Quantitative real-time PCR was performed
using LightCycler technology (Roche) with FastStart DNAMasterPLUS SYBR Green I
(Roche) detection. Each LightCycler capillary was loaded with a total volume of 20 ml
containing template cDNA, 250 nM sense and antisense primers, and 4 ml of
53 SYBR Green Master Mix. In all assays, cDNA was amplified using a standard
program (10 min denaturing step; 50 amplification cycles of 10 s at 95uC, 10 s at
55uC, and 10 s at 72uC). Real-time PCR was performed with the same primer
sequences stated above. Relative quantification of target gene expression was
determined using a mathematical model described in the manufacturer’s guidelines
(Roche). Each PCR assay was performed in triplicate on two separate occasions for
each experiment.
Statistical analysis. Triplicate data for each experiment were presented as
mean 6 SE. Mean comparisons between HSM-treated and control untreated cells
were analyzed using Student’s t-test. P values below 0.05 were considered statistically
significant.
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